Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayFDA Clears Neuromodulator; Bandy Lee Still Not Back at Yale; Most Depressed Cities

News, comments, and analysis from the field of psychiatry, including the FDA’s clearance of a new neuromodulation device for people with significant depression, a phase III safety and efficacy trial of an injectable subcutaneous formulation of olanzapine for schizophrenia, melatonin dependence, and much more.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form